Showing results for:
Inqovi is FDA approved for treatment of adult patients with myelodysplastic syndromes (MDS), including previously treated and untreated, de novo and secondary MDS with the following French American-British subtypes (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, and chronic myelomonocytic leukemia [CMML]) and intermediate-1, intermediate-2, and high-risk International Prognostic Scoring System groups.
Inqovi® Decitabine and cedazuridine
Enasidenib (Idhifa®) is FDA approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation. The drug is approved for use with a companion diagnostic, the RealTime IDH2 Assay, which is used to detect specific mutations in the IDH2 gene in patients with AML.
Idhifa® Enasidenib
Fedratinib is indicated for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF).
Inrebic® Fedratinib
Ibritumomab tiuxetan is FDA approved to treat people who have relapsed or refractory, low-grade or follicular non-Hodgkin lymphoma (NHL), including patients with follicular NHL that did not respond to therapy with rituximab. It is also FDA approved to treat patients with previously untreated follicular NHL who achieve a partial or complete response to first-line chemotherapy. This drug is a monoclonal antibody with an attached radioisotope to deliver radiation therapy to the lymphoma cells.
Zevalin® Ibritumomab tiuxetan
Ibrutinib has been FDA-approved to treat:Patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (SLL) with 17p deletion.Patients with Waldenström macroglobulinemia (WM).Adult and pediatric patients age 1 year and older with chronic graft versus host disease (cGVHD) after failure of one or more lines of systemic therapy.
Imbruvica® Ibrutinib
Idarubicin is FDA approved in combination with other antileukemic drugs to treat people who have acute myeloid leukemia in adults.
Idamycin® Idarubicin
Idecabtagene vicleuce is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma after two or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.
Abecma® Idecabtagene vicleucel
Idelalisib is FDA approved to treat patients with relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
Zydelig® Idelalisib
Ifosfamide is an FDA-approved cancer therapy that is used to treat several types of cancer including acute lymphoblastic leukemia and non-Hodgkin lymphoma. It may cause temporary loss of hair in some people. After treatment has ended, normal hair growth should return.
Ifex® Ifosfamide
Imatinib mesylate is FDA approved to treatNewly diagnosed adult and pediatric patients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in chronic phasePatients with Philadelphia chromosome positive chronic myeloid leukemia (Ph+ CML) in blast crisis (BC), accelerated phase (AP), or in chronic phase (CP) after failure of interferon-alpha therapyAdult patients with relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL)Pediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) in combination with chemotherapyAdult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with PDGFR (platelet-derived growth factor receptor) gene re-arrangements as determined with an FDA-approved testAdult patients with hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukemia (CEL) who have the FIP1L1-PDGFRα fusion kinase (mutational analysis or FISH demonstration of CHIC2 allele deletion) and for patients with HES and/or CEL who are FIP1L1- PDGFRα fusion kinase negative or unknown.
Gleevec® Imatinib mesylate
Imetelstat is FDA approved for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
Rytelo Imetelstat
Inotuzumab ozogamicin is FDA approved for the treatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1 year and older.
Besponsa® Inotuzumab Ozogamicin
Interferons are substances naturally produced by cells in the body to help fight infections and tumors. They may also be synthetic versions of these substances. Interferon alfa-2a is FDA approved to treat people who have hairy cell leukemia and Philadelphia chromosome positive chronic myeloid leukemia who are minimally pretreated (within 1 year of diagnosis). It may cause a temporary loss of hair. After treatment has ended, normal hair growth should return.
Roferon®-A Interferon alfa-2a
Interferons are substances naturally produced by cells in the body to help fight infections and tumors. They may also be synthetic versions of these substances.Interferon alfa-2b is FDA approved to treat people who have hairy cell leukemia, polycythemia vera and aggressive follicular non-Hodgkin lymphoma.
Intron® A Interferon alfa-2b BESREMi®
Isatuximab-irfc is FDA approvedIn combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of therapy.
Sarclisa® Isatuximab-irfc
Ivosidenib is FDA approved for the treatment of patients with a susceptible IDH1 mutation as detected by an FDA-approved test in:Newly diagnosed acute myeloid leukemia (AML)In combination with azacitidine or as monotherapy for the treatment of newly diagnosed AML in adults 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy Relapsed or refractory AMLFor the treatment of adult patients with relapsed or refractory AMLRelapsed or refractory myelodysplastic syndromes (MDS) For the treatment of adult patients with relapsed or refractory myelodysplastic syndromes
Tibsovo® Ivosidenib
Ixazomib is FDA approved in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
NINLARO® Ixazomib
Ponatinib is FDA approved for the treatment of adult patients with:Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)Newly diagnosed Ph+ ALL, in combination with chemotherapy.This indication is approved under accelerated approval based on minimal residual disease (MRD)-negative complete remission (CR) at the end of induction. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).As monotherapy in Ph+ ALL for whom no other kinase inhibitors are indicated or T315I-positive Ph+ ALL.Chronic Myeloid Leukemia (CML)Chronic phase (CP) CML with resistance or intolerance to at least two prior kinase inhibitors.Accelerated phase (AP) or blast phase (BP) CML for whom no other kinase inhibitors are indicated.T315I-positive CML (chronic phase, accelerated phase, or blast phase).Limitations of Use: ICLUSIG is not indicated and is not recommended for the treatment of patients with newly diagnosed CP-CML.
Iclusig® Ponatinib
Romidepsin is FDA approved for the treatment of patients with cutaneous T-cell lymphoma (CTCL) who have received at least one prior systemic therapy and treatment of patients with peripheral T-cell lymphoma (PTCL) who have received at least one prior therapy.
Istodax® Romidepsin